Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran
- 1 May 2002
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 61 (5) , 1830-1839
- https://doi.org/10.1046/j.1523-1755.2002.00314.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Suspected iron dextran-related adverse drug events in hemodialysis patientsAmerican Journal of Kidney Diseases, 2001
- Proposed Revisions to the Declaration of Helsinki — Will They Weaken the Ethical Principles Underlying Human Research?New England Journal of Medicine, 1999
- Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextransAmerican Journal of Kidney Diseases, 1999
- Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trialAmerican Journal of Kidney Diseases, 1999
- The safety of intravenous iron dextran in hemodialysis patientsAmerican Journal of Kidney Diseases, 1996
- Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patientsNephrology Dialysis Transplantation, 1996
- Efficacy of oral iron therapy in patients receiving recombinant human erythropoietinAmerican Journal of Kidney Diseases, 1995
- Iron Deficiency in Maintenance Hemodialysis Patients: Assessment of Diagnosis Criteria and of Three Different Iron TreatmentsNephron, 1991
- Iron Balance in Hemodialysis PatientsAnnals of Internal Medicine, 1977
- Dextran-Induced AnaphylaxisPublished by American Medical Association (AMA) ,1967